Friday, February 15, 11:58 AM
IGI Laboratories (IG +2.2%) trades up after signing a three-year agreement with Juventio LLC to manufacture and supply finished dose forms of certain cosmetic and OTC products and formulations owned and developed by IGI. The products utilize encapsulation technology trademarked as Novasome for which the company currently holds an exclusive license.
Comment![Healthcare, On the Move]
Friday, November 16, 2012, 3:44 PM
Not all closed-end funds trade at premiums to NAV, and for the ones at discounts, recent declines in their stock price - but not their value - has made them even more attractive. The favorites of UBS' Sangeeta Marfatia: IGI, [[iGR]], HPS, and HTD.